MeSH term
Frequency | Condition_Probility | Amino Acid Sequence | 2 | 0.0 |
Genetic Complementation Test | 2 | 0.0 |
Molecular Sequence Data | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 10 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Aged | 10 | 0.0 |
Comparative Study | 5 | 0.0 |
Humans | 18 | 0.0 |
Immunohistochemistry | 7 | 0.0 |
Male | 9 | 0.0 |
Middle Aged | 14 | 0.0 |
Neoplasm Staging | 9 | 0.0 |
Prognosis | 9 | 0.0 |
Protein p53/*metabolism | 2 | 0.0 |
Tumor Markers, Biological/*analysis | 4 | 0.0 |
Adult | 11 | 0.0 |
Aged, 80 and over | 5 | 0.0 |
Breast Neoplasms/*blood supply/metabolism/pathology | 2 | 66.0 |
Female | 14 | 0.0 |
Lymphatic Metastasis | 4 | 0.0 |
Receptors, Estrogen/metabolism | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 2 | 0.0 |
Retrospective Studies | 5 | 0.0 |
Survival Rate | 2 | 0.0 |
Microcirculation/pathology | 3 | 3.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
Disease-Free Survival | 2 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
Cell Division | 2 | 0.0 |
Ki-67 Antigen/analysis | 2 | 0.0 |
Neovascularization, Pathologic/genetics/pathology | 2 | 20.0 |
Analysis of Variance | 2 | 0.0 |
Antigens, CD/analysis | 2 | 0.0 |
Neovascularization, Pathologic/*pathology | 2 | 1.0 |
*Neovascularization, Pathologic | 2 | 0.0 |
Survival Analysis | 2 | 0.0 |
Ki-67 Antigen/metabolism | 2 | 0.0 |
Microcirculation | 2 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
